Search
Close this search box.
IGC Pharma, INC.

About US

We are a focused
CLINICAL-STAGE PHARMACEUTICAL COMPANY

Our purpose is to improve the health and well-being of women and their families through the discovery and development of innovative therapies for neurological disorders like Alzheimer’s disease, bringing these therapies to market. 

Formerly known as India Globalization Capital, Inc., we were incorporated in Maryland on April 25, 2005. Our fiscal year is the 52- or 53-week period ending March 31. 

Most of our revenue currently comes from OTC products, and we anticipate growth from our investigational Alzheimer’s drugs. In fiscal 2022, IGC-AD1, our Phase 2 drug, showed promise in reducing neuropsychiatric symptoms in Alzheimer’s patients. Furthermore, our portfolio of synthetic molecules encompasses an additional four compounds, all with a singular mission – to transform the landscape of Alzheimer’s treatment. LMP targets neuroinflammation, Aβ plaques, and neurofibrillary tangles. TGR-63 is designed to disrupt the progression of Alzheimer’s disease by targeting Aβ plaques. IGC-M3 aims to inhibit Aβ plaque aggregation, potentially making a profound impact on early-stage Alzheimer’s. IGC-1C focuses on tau and neurofibrillary tangles in a forward-thinking approach to Alzheimer’s therapy. 

 Committed to scientific excellence and patient-centered innovation, our goal is to advance the understanding and treatment of various brain-related conditions. 

We are committed to INTRODUCING GROUNDBREAKING therapies to market

With a mission to improve the lives of millions affected by neurological disorders like Alzheimer’s disease. Our goal is to provide relief to those suffering from these conditions, while advancing the understanding and treatment of women’s health needs throughout their lives.